GILD Gilead Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GILD

Price (delayed)

$77.65

Market cap

$96.76B

P/E Ratio

16.49

Dividend/share

$2.98

EPS

$4.71

Enterprise value

$116.03B

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
The company's net income has surged by 76% YoY and by 7% QoQ
GILD's EPS has surged by 76% year-on-year and by 7% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.gilead.com/
Peers: AMGN VRTX ABBV ILMN

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$96.76B
Enterprise value
$116.03B
Valuations
Price to earnings (P/E)
16.49
Price to book (P/B)
4.34
Price to sales (P/S)
3.54
EV/EBIT
14.15
EV/EBITDA
10.81
EV/Sales
4.24
Earnings
Revenue
$27.39B
EBIT
$8.2B
EBITDA
$10.74B
Free cash flow
$7.85B
Per share
EPS
$4.71
Free cash flow per share
$6.29
Book value per share
$17.91
Revenue per share
$21.95
TBVPS
$21.56
Balance sheet
Total assets
$62.37B
Total liabilities
$40.13B
Debt
$24.98B
Equity
$22.31B
Working capital
$4.04B
Liquidity
Debt to equity
1.12
Current ratio
1.34
Quick ratio
0.98
Net debt/EBITDA
1.8
Margins
EBITDA margin
39.2%
Gross margin
78.8%
Net margin
21.4%
Operating margin
30.2%
Efficiency
Return on assets
9.4%
Return on equity
27.4%
Return on invested capital
24.2%
Return on capital employed
16.3%
Return on sales
29.9%
Dividend
Dividend yield
3.84%
DPS
$2.98
Payout ratio
63.3%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
1.37%
1 week
3.01%
1 month
-3.17%
1 year
-11.66%
YTD
-9.55%
QTD
3.62%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$27.39B
Gross profit
$21.59B
Operating income
$8.26B
Net income
$5.88B
Gross margin
78.8%
Net margin
21.4%
The company's net income has surged by 76% YoY and by 7% QoQ
Gilead Sciences's net margin has surged by 74% YoY and by 7% QoQ
The operating income has grown by 38% year-on-year but it has declined by 2.5% since the previous quarter
The operating margin has grown by 37% YoY but it has contracted by 2.3% from the previous quarter

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
GILD P/E details
P/E
16.49
P/B
4.34
P/S
3.54
EV/EBIT
14.15
EV/EBITDA
10.81
EV/Sales
4.24
GILD's EPS has surged by 76% year-on-year and by 7% since the previous quarter
GILD's P/E is 74% below its 5-year quarterly average of 62.7 and 13% below its last 4 quarters average of 18.9
The stock's price to book (P/B) is 8% less than its last 4 quarters average of 4.7 but 3.3% more than its 5-year quarterly average of 4.2
Gilead Sciences's equity has increased by 6% YoY and by 5% from the previous quarter
GILD's price to sales (P/S) is 4.3% less than its last 4 quarters average of 3.7

Efficiency

How efficient is Gilead Sciences business performance
GILD's return on assets has surged by 81% year-on-year and by 7% since the previous quarter
The company's return on equity has surged by 69% YoY and by 5% QoQ
Gilead Sciences's ROIC has soared by 59% YoY
GILD's return on sales is up by 47% year-on-year

Dividends

What is GILD's dividend history
Dividend details
DPS
$2.98
Dividend yield
3.84%
Payout ratio
63.3%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 55% higher than its total liabilities
Gilead Sciences's current ratio has increased by 31% QoQ and by 3.1% YoY
The quick ratio has grown by 26% from the previous quarter and by 2.1% YoY
Gilead Sciences's debt is 12% higher than its equity
The company's debt to equity fell by 7% YoY and by 6% QoQ
Gilead Sciences's equity has increased by 6% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.